BECAUSE HYPERTENSION has long been ascribed to increased peripheral resistance,' its treatment has been primarily directed toward blood pressure reduction by decreasing vascular resistance. Beta-adrenergic receptor stimulation results in peripheral vasodilatation, and at first thought inhibition of beta receptors in the treatment of hypertension seems paradoxical. However, betaadrenergic inhibition also reduces cardiac output,2 another hemodynamic variable directly affecting arterial pressure. Perhaps the effectiveness of beta-adrenergic receptor blocking drugs in treatment of diastolic hypertension3-7 may be related to this effect, but hemodynamic studies during long-term treat- ment have not yet been reported. Hemodynamic studies were performed on seven patients before and during treatment. Each study was conducted in a manner similar to that described previously.2' 9 In brief, catheters were inserted centrally through a brachial artery and a contralateral antecubital vein for recording pressures, injecting indocyanine-green dye, and obtaining indicator-dilution curves for determination of cardiac output. After obtaining base-line studies in the supine position, isoproterenol was infused intravenously at increasing rates (1, 2, and 3 ,ug/min). These studies constitute the "before treatment" measurements. After oral propranolol treatment for some time and after significant reduction of arterial pressure, some patients were rehospitalized for investigation of the hemodynamic mechanisms underlying the reduction in their arterial pressure. Inhibition of beta-adrenergic activity was confirmed by failure of isoproterenol to increase heart rate at the previously infused rates. Cardiac output was calculated using the Stewart-Hamilton method10' 11 and is expressed as cardiac index (ml/ min/M2). Total peripheral resistance is expressed as mm Hg/ml/min as the quotient of mean arterial pressure divided by cardiac output. Left ventricular ejection rate is expressed as ml/sec/ m2 by dividing stroke index by left ventricular ejection time.
Results

Hypotensive Effects
Arterial pressure was reduced in 16 of the 19 patients studied. For the entire group, Thus, at the office, as well as at home, arterial pressure was significantly reduced in over 80% of patients selected for treatment. Hemodynamic functions were measured before and during propranolol therapy in seven patients, and their results are presented in table 4. The second hemodynamic study was performed 10 months (average) after propranolol was begun (range, 4 to 15 months), and at times when home treatment blood pressure was significantly lower than pretreatment pressures. Associated with the reduction in arterial pressures (systolic, diastolic, and mean) in all seven patients was a significant decrease in cardiac output (6,130 to 4,615 ml/min; P < 0.005). The reduction in output is explained solely by decreased heart rate from 88 to 65 beats/min (P < 0.005), since stroke volume remained unchanged. Despite the lack of change in stroke index, left ventricular ejection rate was significantly reduced (146 to 129 ml/sec /m2; P <0.025) because of prolongation of left ventricular ejection time (uncorrected for heart rate). When ejection time was corrected for heart rate, however, there was no significant difference before and during drug treatment. Total peripheral resistance increased in five and decreased in two patients (in one, only minimally). Thus, arterial pressure was reduced in all seven hypertensive patients, primarily by a reduction in cardiac output, and in five the pressure fall was accompanied by increased total peripheral resistance. Isoproterenol was infused intravenously in all patients at the conclusion of the hemodynamic studies, and the drug failed to increase heart rate even at infusion rates as high as 3 ,ug/min.
Discussion
The results of this study show that in some hypertensive patients beta-adrenergic blocking therapy, with propranolol, is effective in reducing arterial pressure with little or no side effects and no orthostatic hypotension. These findings seem paradoxical for two reasons. First, the drug fails to reduce arterial pressure immediately following its intravenous administration but only reduces cardiac output and heart rate.2 Secondly, arterial pressure is reduced with prolonged treatment in hypertensive patients by a mechanism which does not decrease total peripheral resistance.
The mechanism by which arterial pressure is lowered must be attributed to prolonged reduction of cardiac output. Output has remained reduced by approximately 25% of pretreatment levels after 10 months' (average) therapy, and in some patients this has been maintained for as long as 15 months. That this reduction is related to persistent betaadrenergic inhibition is shown by the failure of isoproterenol to increase heart rate. This indicates that with prolonged inhibition of beta-adrenergic activity there is no physiological "tolerance" of the heart. We have previously shown that output was reduced by 20% following intravenous administration of propranolol.2
These studies also confirm our previous observation that output is lowered in patients with hypertension by reduction in heart rate,2 and further suggest that by prolonged inhibition of beta-adrenergic activity, arterial pressure may be reduced. It seems unlikely that only patients with elevated cardiac output respond to beta-adrenergic inhibition since several patients who responded to propranolol had normal or low-normal cardiac output prior to therapy.
Reduction in cardiac output and left ventricular ejection rate does not represent latent cardiac failure because of the slowing of heart rate, marked symptomatic improvement, absence of shortness of breath, unchanged cardiac silhouette without pulmonary congestion, and in one patient, actual reduction of cardiopulmonary volume. That arterial pressure reduction is not attributable to a nonspecific tranquilizing effect was demonstrated to us by the persistent reduction in pressure at more stressful times in some patients, and when one patient was severely depressed.
The hemodynamic findings suggest to us a new approach whereby arterial pressure may be reduced in hypertension. It 
